Key facts
- Notable investors include Innovation and Technology, New Jersey Commission on Science, Pier 70 Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Antingenix America
- ·The full record, as it builds
Funding rounds
No funding rounds for Antingenix America are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Antingenix America
Operator of immunology research reagents intended for use in biological, clinical, and laboratory-based studies of immune system function. The company's platform supplies antibody products, enzyme-linked immunosorbent assay components, multiplex assay systems, recombinant proteins, assay development materials, and related accessory, enabling biomedical research institutions, diagnostic laboratories, and life sciences organizations to conduct reproducible immunological analyses, develop assays, and support experimental validation across cytokine, cell marker, and immune signalling research.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Website
- antigenix.com/
- Ownership
- Privately Held (backing)
Antingenix America doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Antingenix America shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Antingenix America in its N-PORT filings yet. We sweep new filings monthly.